Considerations for the use of proton-pump inhibitors in older adults

Consultant Pharmacist

Volumn 27, Issue 2, 2012, Pages 114-120

  Desilets, Alicia R ^a   Asal, Nicole J ^b   Dunican, Kaelen C ^c  

^a Massachusetts College of Pharmacy and Health Sciences Manchester   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Adverse events; Elderly; Gastroesophageal reflux disease; Older adults; Proton pump inhibitors; Safety

Indexed keywords

ATAZANAVIR; CALCIUM CARBONATE; CEFPODOXIME; CLOPIDOGREL; KETOCONAZOLE; LANSOPRAZOLE; LEVOTHYROXINE; OMEPRAZOLE; PANTOPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR;

ADULT; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CYANOCOBALAMIN DEFICIENCY; DRUG SAFETY; GASTRIC HYPERACIDITY; GASTROINTESTINAL REFLUX; GROUPS BY AGE; HIP FRACTURE; HUMAN; IRON DEFICIENCY; MINERAL DEFICIENCY; REVIEW; RISK FACTOR; UNITED STATES; VERTEBRA FRACTURE;

EID: 84857692820     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2012.114     Document Type: Review

References (62)

1. Greenwald DA. Aging, the gastrointestinal tract, and risk of acid-related disease. Am J Med 2004;117 Suppl 5A:8-13.
2. Franceschi M, Di Mario F, Leandro G et al. Acid-related disorders in the elderly. Best Pract Res Clin Gastroenterol 2009;23:839-48.
3. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999;15:15-28. (Pubitemid 29358484)
4. Wilder-Smith C, Halter F, Ernst T et al. Loss of acid suppression during dosing with H2-receptor antagonists. Aliment Pharmacol Ther 1990;4 Suppl 1:15-27. (Pubitemid 20271090)
5. Burge R, Dawson-Hughes B, Solomon DH et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-75. (Pubitemid 46797130)
6. Gronholz MJ. Prevention, diagnosis, and management of osteoporosis-related fracture: a multifactoral osteopathic approach. J Am Osteopath Assoc 2008;108:575-85.
7. Yang YX, Lewis JD, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53. (Pubitemid 46021498)
8. Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-26.
9. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83. (Pubitemid 44306164)
10. Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the women's health initiative. Arch Intern Med 2010;170:765-71.
11. Roux C, Briot K, Gossec L et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009;84:13-9.
12. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-9.
13. Corley DA, Kubo A, Zhao W et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93-101.
14. Yu EW, Blackwell T, Ensrud KE et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83:251-9.
15. McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010;26:624-31.
16. Parkman HP, Urbain JL, Knight LC et al. Effect of gastric acid suppressants on human gastric motility. Gut 1998;42:243-50. (Pubitemid 28212180)
17. Dinsmore JE, Jackson RJ, Smith SD. The protective role of gastric acidity in neonatal bacterial translocation. J Pediatr Surg 1997;32:1014-6. (Pubitemid 27349015)
18. Lewis SJ, Franco S, Young G et al. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996;10:557-61. (Pubitemid 26254799)
19. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006;23:3-10. (Pubitemid 43381161)
20. Theisen J, Nehra D, Citron D et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2000;4:50-4.
21. Thorens J, Froehlich F, Schwizer W et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39:54-9. (Pubitemid 26239105)
22. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009;15:1554-80.
23. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008;14:929-31. (Pubitemid 351838602)
24. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-56; quiz 2057.
25. Howell MD, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784-90.
26. Meijvis SC, Cornips MC, Voorn G et al. Microbial evaluation of proton pump inhibitors and the risk of pneumonia. Eur Respir J 2011;38:1165-72.
27. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010;31:1165-77.
28. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008;149:391-8.
29. Roughead EE, Ramsay EN, Pratt NL et al. Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia. Med J Aust 2009;190:114-6.
30. Dublin S, Walker RL, Jackson ML et al. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010;19:792-802.
31. Gau JT, Acharya U, Khan S et al. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr 2010;10:45.
32. Schenk BE, Festen HP, Kuipers EJ et al. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 1996;10:541-5. (Pubitemid 26254797)
33. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009;104 Suppl 2:5-9.
34. Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992;14:288-92.
35. Festen HP, Klinkenberg-Knol EC, Kuipers EJ et al. Cobalamin absorption during omeprazole treatment: short and long-term studies. Esophageal, Gastric, and Duodenal Disorders 1993;4:A77.
36. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. Annu Rev Nutr 1999;19:357-77.
37. Ivanovich P, Fellows H, Rich C. The absorption of calcium carbonate. Ann Intern Med 1967;66:917-23.
38. Straub DA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract 2007;22:286-96.
39. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011;56:931-50.
40. Bezwoda W, Charlton R, Bothwell T et al. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Lab Clin Med 1978;92:108-16. (Pubitemid 8384452)
41. Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 2004;97:887-9. (Pubitemid 39249673)
42. Hutchinson C, Geissler CA, Powell JJ et al. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007;56:1291-5. (Pubitemid 47300432)
43. Skikne BS, Lynch SR, Cook JD. Role of gastric acid in food iron absorption. Gastroenterology 1981;81:1068-71. (Pubitemid 11029686)
44. Thomson AB, Sauve MD, Kassam N et al. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010;16:2323-30.
45. Lahner E, Annibale B, Delle Fave G. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther 2009;29:1219-29.
46. Centanni M, Gargano L, Canettieri G et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 2006;354:1787-95.
47. Sachmechi I, Reich DM, Aninyei M et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract 2007;13:345-9.
48. Tran JQ, Gerber JG, Kerr BM. Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2001;40:207-26. (Pubitemid 32324451)
49. Labenz J, Petersen KU, Rosch W et al. A summary of food and drug administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2003;17:1015-9. (Pubitemid 36560801)
50. Plavix. Prescribing information. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2011.
51. Abraham NS, Hlatky MA, Antman EM et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010;105:2533-49.
52. Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17.
53. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44.
54. O'Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97.
55. Rassen JA, Choudhry NK, Avorn J et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009;120:2322-9.
56. Ray WA, Murray KT, Griffin MR et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010;152:337-45.
57. Stockl KM, Le L, Zakharyan A et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010;170:704-10.
58. Harmsze AM, van Werkum JW, Taubert D et al. Esomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel's active metabolite. Ann Pharmacother 2011;45:542-3.
59. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15. (Pubitemid 350106708)
60. George CJ, Korc B, Ross JS. Appropriate proton pump inhibitor use among older adults: a retrospective chart review. Am J Geriatr Pharmacother 2008;6:249-54.
61. Bjornsson E, Abrahamsson H, Simren M et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006;24:945-54. (Pubitemid 44326375)
62. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk. Am J Gastroenterol 2009;104 Suppl 2:27-32.